Myovant Sciences Ltd (MYOV)

[MDizzle]

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE

the first once-daily treatment for heavy menstrual bleeding associated with uterine fibroids


In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from baseline. Myovant and Pfizer will jointly commercialize MYFEMBREE, with product availability expected in June.